{
     "PMID": "15474910",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20050301",
     "LR": "20160526",
     "IS": "0920-9964 (Print) 0920-9964 (Linking)",
     "VI": "71",
     "IP": "2-3",
     "DP": "2004 Dec 1",
     "TI": "Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects.",
     "PG": "383-92",
     "AB": "There is strong evidence that hippocampal 5-hydroxytryptamine (5-HT) systems are affected in schizophrenia and hence we have studied a number of markers of the 5-HT system in hippocampi from subjects with schizophrenia. Using in situ radioligand binding with autoradiography we measured [(3)H]proplyamino-8-hydroxy-1,2,3,4-tetrahydronapthalene, [(3)H]ketanserin and [(3)H]sumatriptan binding in hippocampi from 20 schizophrenic and 20 control subjects. There were significant decreases in the density of [(3)H]ketanserin binding to the 5-HT(2A) receptor (5-HT(2A)R) in the Cornu Ammonis (CA) 3 (p=0.006), CA 1 (stratum radiatum p=0.02; pyramidal layer p=0.0008) and subiculum (pyramidal layer p=0.0004), as well as methiothepin-insensitive [(3)H]sumatriptan binding to the 5-HT(1F)R in the CA 1 (p=0.016), stratum radiatum/lacunosum moleculare (p=0.04) and subiculum (p=0.015) from subjects with schizophrenia. There were no differences in the densities of 5-HT(1A)R, 5-HT(1D)R or 5-HT(4)R in hippocampi from subjects with schizophrenia. These data support the hypothesis that regionally specific reductions in the density of the 5-HT(2A)R and 5-HT(1F)R are a component of the pathological processes underlying schizophrenia.",
     "FAU": [
          "Scarr, Elizabeth",
          "Pavey, Geoffrey",
          "Copolov, David",
          "Dean, Brian"
     ],
     "AU": [
          "Scarr E",
          "Pavey G",
          "Copolov D",
          "Dean B"
     ],
     "AD": "The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Australia.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "Netherlands",
     "TA": "Schizophr Res",
     "JT": "Schizophrenia research",
     "JID": "8804207",
     "RN": [
          "0 (Receptors, Serotonin)",
          "0 (Serotonin Antagonists)",
          "0 (Serotonin Receptor Agonists)",
          "0 (Tetrahydronaphthalenes)",
          "8R78F6L9VO (Sumatriptan)",
          "97F9DE4CT4 (Ketanserin)"
     ],
     "SB": "IM",
     "MH": [
          "Adult",
          "Aged",
          "Autoradiography",
          "Binding Sites",
          "Female",
          "Hippocampus/*metabolism/*pathology",
          "Humans",
          "Ketanserin/pharmacokinetics",
          "Male",
          "Middle Aged",
          "Radioligand Assay",
          "Receptors, Serotonin/*metabolism",
          "Schizophrenia/*metabolism/*pathology",
          "Serotonin Antagonists/pharmacokinetics",
          "Serotonin Receptor Agonists/pharmacokinetics",
          "Sumatriptan/pharmacokinetics",
          "Tetrahydronaphthalenes/pharmacokinetics"
     ],
     "EDAT": "2004/10/12 09:00",
     "MHDA": "2005/03/02 09:00",
     "CRDT": [
          "2004/10/12 09:00"
     ],
     "PHST": [
          "2004/02/06 00:00 [received]",
          "2004/02/06 00:00 [revised]",
          "2004/02/18 00:00 [accepted]",
          "2004/10/12 09:00 [pubmed]",
          "2005/03/02 09:00 [medline]",
          "2004/10/12 09:00 [entrez]"
     ],
     "AID": [
          "S0920996404000593 [pii]",
          "10.1016/j.schres.2004.02.007 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Schizophr Res. 2004 Dec 1;71(2-3):383-92. doi: 10.1016/j.schres.2004.02.007.",
     "term": "hippocampus"
}